Simcere Pharmaceutical Group
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Simcere Pharmaceutical Group missed estimates on revenue and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank and GAAP earnings per share contracted significantly.
Margins contracted across the board.
Revenue details
Simcere Pharmaceutical Group tallied revenue of $80.9 million. The four analysts polled by S&P Capital IQ hoped for net sales of $85.6 million on the same basis. GAAP reported sales were 9.1% lower than the prior-year quarter's $89.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Non-GAAP EPS came in at $0.07. The three earnings estimates compiled by S&P Capital IQ anticipated $0.05 per share on the same basis. GAAP EPS of $0.12 for Q4 were 25% lower than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 82.3%, 180 basis points worse than the prior-year quarter. Operating margin was 0.3%, 1,040 basis points worse than the prior-year quarter. Net margin was 8.4%, 160 basis points worse than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $79.2 million. On the bottom line, the average EPS estimate is $0.10.
Next year's average estimate for revenue is $356.7 million. The average EPS estimate is $0.46.
Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 233 members out of 243 rating the stock outperform, and 10 members rating it underperform. Among 56 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 52 give Simcere Pharmaceutical Group a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Simcere Pharmaceutical Group is hold, with an average price target of $9.30.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Simcere Pharmaceutical Group the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Simcere Pharmaceutical Group to My Watchlist.